• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Monday

    7/31/23 2:54:35 PM ET
    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email

     

    On Monday, 27 stocks hit new 52-week lows.

    Interesting Points From Today's 52-Week Lows:

    • The largest company by market cap to hit a new 52-week low was Apellis Pharmaceuticals (NASDAQ:APLS).
    • Esports Entertainment (NASDAQ:GMBL) was the smallest company by market cap to set a new 52-week low.
    • Theratechnologies (NASDAQ:THTX)'s stock came under the most pressure, trading down 252.48% to reach a new 52-week low.
    • Artesian Resources (NASDAQ:ARTNA) shares bounced back the most, actually rising 0.04% after hiting a new 52-week low.

    The following stocks set new 52-week lows on Monday:

    • Apellis Pharmaceuticals (NASDAQ:APLS) shares moved down 18.14% on Monday to hit a new 52-week low of $25.48, drifting down 18.14%.
    • Impinj (NASDAQ:PI) shares hit a yearly low of $65.03. The stock was down 2.54% on the session.
    • Artesian Resources (NASDAQ:ARTNA) shares made a new 52-week low of $45.27 on Monday. The stock was down 0.04% for the day.
    • Vanda Pharma (NASDAQ:VNDA) shares hit a yearly low of $5.58. The stock was down 2.61% on the session.
    • Prelude Therapeutics (NASDAQ:PRLD) stock dropped to a yearly low on Monday of $3.92. Shares traded down 1.51%.
    • SWK Holdings (NASDAQ:SWKH) stock hit a yearly low of $15.87. The stock was up 0.38% for the day.
    • Silicom (NASDAQ:SILC) stock hit a yearly low of $29.00. The stock was down 25.43% for the day.
    • Complete Solaria (NASDAQ:CSLR) shares set a new 52-week low of $3.31. The stock traded down 7.95%.
    • Matinas BioPharma Hldgs (AMEX:MTNB) stock hit a new 52-week low of $0.32. The stock was down 8.33% on the session.
    • CEL-SCI (AMEX:CVM) shares set a new 52-week low of $1.51. The stock traded down 6.12%.
    • Dare Bioscience (NASDAQ:DARE) shares reached a new 52-week low of $0.73 on Monday morning, moving up 0.47%.
    • Delta Apparel (AMEX:DLA) shares set a new 52-week low of $8.36. The stock traded down 3.24%.
    • Theratechnologies (NASDAQ:THTX) shares set a new 52-week low of $1.74. The stock traded up 252.48%.
    • Purple Biotech (NASDAQ:PPBT) shares fell to $1.02 on Monday, setting a new 52-week low with a shift of down 4.5%.
    • Datasea (NASDAQ:DTSS) stock set a new 52-week low of $0.71 on Monday, moving down 3.97%.
    • Capstone Green Energy (NASDAQ:CGRN) shares set a new 52-week low of $0.92. The stock traded down 4.9%.
    • GRI Bio (NASDAQ:GRI) shares made a new 52-week low of $3.45 on Monday. The stock was up 2.59% for the day.
    • Pop Culture Gr (NASDAQ:CPOP) stock hit a new 52-week low of $0.39. The stock was down 3.15% on the session.
    • ABVC BioPharma (NASDAQ:ABVC) shares reached a new 52-week low of $2.46 on Monday morning, moving down 5.58%.
    • Biolase (NASDAQ:BIOL) shares hit a yearly low of $5.75. The stock was down 10.07% on the session.
    • Takung Art (AMEX:TKAT) stock achieved a new 52-week low on Monday morning, hitting $0.16 and moving down 14.68%.
    • Bone Biologics (NASDAQ:BBLG) stock set a new 52-week low of $1.24 on Monday, moving down 2.27%.
    • Eightco Holdings (NASDAQ:OCTO) shares made a new 52-week low of $1.30 on Monday. The stock was down 4.14% for the day.
    • Blue Star Foods (NASDAQ:BSFC) stock hit a yearly low of $0.85. The stock was down 13.73% for the day.
    • Esports Entertainment (NASDAQ:GMBL) shares set a new yearly low of $0.40 this morning. The stock was down 6.98% on the session.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ABVC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $APLS
    $ARTNA
    $BBLG

    CompanyDatePrice TargetRatingAnalyst
    Apellis Pharmaceuticals Inc.
    $APLS
    10/15/2025$32.00Overweight
    Wells Fargo
    Impinj Inc.
    $PI
    10/8/2025$200.00Overweight
    Barclays
    Apellis Pharmaceuticals Inc.
    $APLS
    9/26/2025$18.00Neutral → Sell
    Goldman
    Apellis Pharmaceuticals Inc.
    $APLS
    5/9/2025$23.00Buy → Neutral
    BofA Securities
    Apellis Pharmaceuticals Inc.
    $APLS
    5/9/2025$52.00Strong Buy → Outperform
    Raymond James
    Apellis Pharmaceuticals Inc.
    $APLS
    4/29/2025$44.00Overweight
    Cantor Fitzgerald
    Complete Solaria Inc.
    $CSLR
    3/13/2025Buy → Neutral
    Janney
    Apellis Pharmaceuticals Inc.
    $APLS
    12/17/2024$36.00Buy → Neutral
    Goldman
    More analyst ratings

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Apellis Pharmaceuticals with a new price target

    Wells Fargo initiated coverage of Apellis Pharmaceuticals with a rating of Overweight and set a new price target of $32.00

    10/15/25 8:22:24 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Impinj with a new price target

    Barclays initiated coverage of Impinj with a rating of Overweight and set a new price target of $200.00

    10/8/25 8:34:51 AM ET
    $PI
    Industrial Machinery/Components
    Technology

    Apellis Pharmaceuticals downgraded by Goldman with a new price target

    Goldman downgraded Apellis Pharmaceuticals from Neutral to Sell and set a new price target of $18.00

    9/26/25 8:01:10 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO O'Donnell Kevin J bought $250,000 worth of shares (171,233 units at $1.46) and was granted 400,000 shares, increasing direct ownership by 1,987% to 599,985 units (SEC Form 4)

    4 - Eightco Holdings Inc. (0001892492) (Issuer)

    9/11/25 8:07:01 AM ET
    $OCTO

    Director Jennings Frank D bought $200,000 worth of shares (136,986 units at $1.46), increasing direct ownership by 796% to 154,189 units (SEC Form 4)

    4 - Eightco Holdings Inc. (0001892492) (Issuer)

    9/10/25 3:59:46 PM ET
    $OCTO

    Director Caiano Nicola Paul was granted 2,960 shares and bought $500,000 worth of shares (342,466 units at $1.46), increasing direct ownership by 7,105% to 350,288 units (SEC Form 4)

    4 - Eightco Holdings Inc. (0001892492) (Issuer)

    9/10/25 3:58:39 PM ET
    $OCTO

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

    Conference Call and Webcast to Follow WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 29, 2025, during which management will discuss the third quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode 8728050. The

    10/22/25 4:30:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arthur L. Valdez, Jr. Joins Impinj Board of Directors

    Impinj, Inc. (NASDAQ:PI), a leading RAIN RFID provider and Internet of Things pioneer, today announced that Arthur L. Valdez, Jr. has joined its board of directors effective October 20, 2025. "I'm thrilled to welcome Arthur to the Board," said Steve Sanghi, Impinj Board Chair. "As Impinj takes its RAIN RFID solutions deeper into global supply chain and logistics use cases, Arthur's extensive experience in this area will be a tremendous asset. We look forward to Arthur's insights and contributions helping Impinj ascend to the next level." "Arthur's expertise transforming and optimizing strategic supply chain and logistics networks for large consumer-facing companies will be invaluable as

    10/21/25 4:15:00 PM ET
    $PI
    Industrial Machinery/Components
    Technology

    SunPower Announces Record Profit in Q3'25

    OREM, Utah, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SunPower, the "Company," or Nasdaq: "SPWR", a solar technology, services, and installation company, will present its Q3'25 results via webcast today Tuesday, October 21 at 1:00pm ET. Interested parties may access the webcast by registering here or by visiting the Events page within the IR section of the company website: https://investors.sunpower.com/news-events/events. Fellow Shareholders:The preliminary Q3'25 quarterly report of key financial parameters is shown below. The final Q3'25 quarterly report will be the SEC 10Q report expected to be filed on November 12, 2025. SunPower Q3'25 Revenue & Operating Income Statement1     GAAP2 NON-GAAP3

    10/21/25 8:00:00 AM ET
    $CSLR
    $SPWR
    Semiconductors
    Technology

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    SEC Filings

    View All

    Impinj Inc. filed SEC Form 8-K: Leadership Update

    8-K - IMPINJ INC (0001114995) (Filer)

    10/20/25 4:35:25 PM ET
    $PI
    Industrial Machinery/Components
    Technology

    Prelude Therapeutics Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - Prelude Therapeutics Inc (0001678660) (Filer)

    10/17/25 7:40:32 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Apellis Pharmaceuticals Inc.

    144 - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    10/16/25 9:52:58 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sullivan Timothy Eugene exercised 10,000 shares at a strike of $10.03 and sold $280,300 worth of shares (10,000 units at $28.03) (SEC Form 4)

    4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

    10/23/25 4:20:30 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Valdez Arthur L Jr

    4 - IMPINJ INC (0001114995) (Issuer)

    10/22/25 5:07:02 PM ET
    $PI
    Industrial Machinery/Components
    Technology

    SEC Form 3 filed by new insider Valdez Arthur L Jr

    3 - IMPINJ INC (0001114995) (Issuer)

    10/22/25 5:04:28 PM ET
    $PI
    Industrial Machinery/Components
    Technology

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Leadership Updates

    Live Leadership Updates

    View All

    Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

    WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today. Ms. Dorton has more than 30 years of industry expertise and leadership in healthcare and life sciences including service on several boards of public life science companies, executive financial leadership and investment banking. "Katina brings to Prelude an abundance of experience as a strategic and financial advisor to our leadership team," stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. "We welcome her to our board and we look forward to

    10/17/25 7:30:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SPWR to Acquire Sunder Energy to Gain U.S. No. 5 Spot

    OREM, Utah, Sept. 22, 2025 (GLOBE NEWSWIRE) -- SunPower (formerly d/b/a Complete Solaria, Inc.; herein "SunPower," the "Company" or Nasdaq: "SPWR") – a solar technology, services, and installation company – today announced that it has agreed to acquire Sunder Energy, based in South Jordan, Utah, the No. 11 U.S. solar company by installed megawatts as reported by Ohm Analytics. The transaction is scheduled to close this week subject to customary closing conditions. Management will host a call today at 11am PT / 2pm ET to discuss the merger. Interested parties may access the webcast by registering via the link here or by visiting the Events page found within the IR section of the company web

    9/22/25 8:00:00 AM ET
    $CSLR
    $SPWR
    Semiconductors
    Technology

    Callodine Group Appoints Winston Black as Head of Life Sciences Finance Strategy

    Callodine Group ("Callodine") is pleased to announce the appointment of Winston Black as the Head of Callodine's newly formed Life Sciences Finance Strategy. In this role, Mr. Black will lead the firm's efforts in sourcing, underwriting, and managing structured investments across the life sciences sector, with a focus on commercial-stage companies. Mr. Black brings more than 25 years of investment and operational experience, with deep domain expertise in life sciences finance. He has been active in the space since 2005 and has invested over $1 billion in similar strategies across the capital structure. His proven ability to navigate complex transactions and his established network of clin

    7/31/25 8:30:00 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Financials

    Live finance-specific insights

    View All

    Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

    Conference Call and Webcast to Follow WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 29, 2025, during which management will discuss the third quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode 8728050. The

    10/22/25 4:30:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

    Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2025 financial results on Thursday, October 30, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Ape

    10/16/25 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Runway Growth Finance Corp. to Acquire SWK Holdings Corporation

    Acquisition of high-quality portfolio centered on healthcare and life sciences investments Accelerates strategy to diversify and optimize portfolio while adding significant scale Enhances financial profile and is expected to be accretive to net investment income ("NII") MENLO PARK, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (NASDAQ:RWAY) ("Runway Growth" or the "Company"), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced that it has entered into a definitive merger agreement to acquire SWK Holdings Corporation (NASDAQ:SWKH) ("SWK"), a life science focused specialty fi

    10/9/25 5:45:24 PM ET
    $RWAY
    $SWKH
    Finance: Consumer Services
    Finance
    Diversified Financial Services

    $ABVC
    $APLS
    $ARTNA
    $BBLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Blue Star Foods Corp.

    SC 13G/A - Blue Star Foods Corp. (0001730773) (Subject)

    11/14/24 7:34:10 PM ET
    $BSFC